الفهرس 
EtiopathogenesisOnly 14 pages are availabe for public view
 |  | from | 178 |  |  |
| | | from | 178 | | |
Abstract
Central serous chorioretinopathy (CSC or CSCR) is defined as serous retinal detachment with or without pigment epithelial detachment (PED) most commonly seen in the macular region.
Standard initial management of acute classic CSC is a careful observation with modification of various risk factors. Acute CSC has typically an excellent prognosis and self-resolving natural course with almost full visual recovery to the premorbid level.
As chronic CSC may cause an irreversible visual decline, some clinicians may plan to treat early.
There are various treatment modalities; Photodynamic therapy (PDT), Subthreshold micropulse laser (SML), Laser photocoagulation, Transpupillary thermotherapy (TTT), Antagonists of mineralocorticoid receptors (MR) and glucocorticoid receptors, Anti-VEGFs and Other systemic treatment strategies.
Due to adverse effects of the commonly used treatment modalities (PDT, SML), anti-VEGFs became a simple, safe, non-expensive and effective treatment of chronic cases of CSC.
Bevacizumab is a full-length, recombinant IgG1 humanized monoclonal antibody directed against all the biologically active isoforms of VEGF-A to prevent the interaction between VEGF-A and its receptors on the surface of endothelial cells stopping the intracellular signaling pathway.
The current study was performed to evaluate the efficacy and safety of Bevacizumab in treatment of chronic CSC.
This meta-analysis included eight prospective studies that were published until 2021. They were two RCTs and six case series, and about 105 patients with cCSC (105 eyes) participated in these studies. The mean age ranged between 37.2 and 63 years. The baseline of the mean BCVA ranged between 0.2 and 0.76 log.MAR and the baseline of the CMT was between 304.5 to 557 μm.
For Bevacizumab, a vial of 0.05 ml containing 1.25 mg was injected in six of the included studies while a vial of 0.1 ml containing 2.50 mg was injected in the remaining two studies.
This study demonstrated a non-statistically significant change in the mean of BCVA improvement and CMT reduction at one month follow up while at three and six-month follow-ups, improvement was significant.
None of the included studies in our Metanalysis reported any adverse event following intravitreal injection of bevacizumab.
Bevacizumab is a possible alternative in case of chronic central serous chorioretinopathy.